The FDA has approved a combination tablet consisting of sitagliptin and metformin hydrochloride (Janumet XR, Merck) to treat type 2 diabetes. The once-daily agent is indicated as an adjunct to diet and exercise to improve glycemic control.
Abstract: Merck.
